What is CBG? Cannabigerol, or CBG, is the cannabinoid the plant builds many others from, which is why people call it the "mother cannabinoid." It isn't intoxicating at the doses studied so far, it usually shows up in small amounts, and it's growing in popularity, often in products that pair it with THC or CBD. Here's how CBG forms, what research has actually tested, and what it means for labels and drug tests.
What is CBG, and why is it called the mother cannabinoid?
Scientists first isolated CBG in 1964, from an extract of hashish. Its fame comes from its acid form, CBGA (cannabigerolic acid), which sits at the start of the plant's cannabinoid assembly line. The plant turns CBGA into the acids that later become THC, CBD and CBC, which is where the mother-cannabinoid nickname comes from.
CBG itself is what CBGA becomes when it's heated or dried, the same shift that turns THCA into THC. You'll see both forms on lab reports, and both usually appear in modest amounts. For a broader map of these compounds, see our guide to the main types of cannabinoids.
How CBGA becomes THCA, CBDA and CBCA as the plant matures
Inside the flower's trichomes, the tiny resin glands on the buds, enzymes pick up CBGA and reshape it into one of three acids:
- THCA, which heat turns into THC
- CBDA, which heat turns into CBD
- CBCA, which heat turns into CBC
Which acid dominates depends on the plant's genes. Researchers have traced much of it to a single genetic locus, often called the B locus, which carries the instructions for converting CBGA. One version steers it toward THCA, another toward CBDA, and a plant that inherits one of each makes a mix. In a typical plant, much of the CBGA is converted as the flowers develop, so relatively little remains as CBGA or CBG by the time the flower is dried and tested.
Our article on CBC follows one of those three branches in more detail.
Why most flower holds little CBG, and how breeders raised it
Because the plant converts so much of its CBGA, CBG usually ends up as a minor player, present in much smaller quantities than THC or CBD. That's also why CBG-rich flower is uncommon.
The exception came from plant genetics. Researchers studying fiber hemp found plants that were strongly dominated by CBG. The cause was a barely functional version of the B-locus gene: plants carrying two copies couldn't convert most of their CBGA, so it piled up. Crossing those plants with THC-dominant and CBD-dominant lines showed the trait passed down in a predictable way, which is what makes breeding for CBG possible.
Today, CBG-dominant cannabis exists. In one U.S. survey, people described using products in which CBG made up more than half of the cannabinoid content.
What research explores, with study types
CBG research spans lab dishes, animals and a small number of people. The type of study matters as much as the result:
| Study type | What it looked at | What it can't tell you |
|---|---|---|
| Cell and animal studies | Inflammation, bacteria, fungi and nerve signaling in lab models | Whether any effect carries over to people |
| Online survey (2022) | 127 U.S. adults who used CBG-dominant products | Whether CBG caused any change, since there was no comparison group |
| Small trial, healthy adults (2024) | One 20 mg dose of CBG versus placebo in 34 people | Effects of regular use, or in anyone with a diagnosed condition |
| Small trial, veterans (2026) | Daily CBG for four weeks versus placebo, focused on sleep | Firm conclusions, since many participants didn't complete the study as planned |
Lab and animal studies
Much of the interest in CBG starts here. In lab models, CBG has shown anti-inflammatory, antibacterial and antifungal activity, and it has lowered levels of inflammatory signaling molecules such as TNF-alpha and IL-1 beta. These results describe biological activity in cells and animals. They don't tell you what a CBG gummy will do for a person.
The survey
In the 2022 survey, people most often said they used CBG for anxiety, chronic pain, depression and poor sleep, and most rated their symptoms as improved. Self-reports from a self-selected online group are a reason to run trials, not proof, and the authors themselves called for randomized controlled trials.
The trials
The two placebo-controlled trials point in different directions. In the 2024 study, participants reported lower anxiety and stress after a single dose of CBG than after placebo, and they did better on a verbal memory test. That was one dose, in healthy volunteers, in sessions run over video calls, so it says little about regular use.
In the 2026 veterans study, people took 25 mg of CBG a day for two weeks and then 50 mg a day for two more. Sleep scores improved in both the CBG and placebo groups, with no statistically significant difference between them. Only 35 of the 63 people who started finished without major protocol problems, and the authors wrote that no firm conclusion about CBG and sleep could be drawn.
Putting it together
CBG has interesting lab activity and a handful of small human studies with mixed results. None of it shows that CBG prevents, relieves or reverses any condition, and no CBG medicine has been approved. If you're pregnant or breastfeeding, take medications or manage a health condition, talk with a clinician before trying CBG or any cannabis product.
Is CBG intoxicating? Psychoactive versus intoxicating
Two words get mixed up here. "Psychoactive" means a substance acts on the brain. "Intoxicating" means it impairs you or produces a high. CBG is psychoactive in the broad sense: in lab studies it potently activates alpha-2 adrenergic receptors and moderately blocks 5-HT1A serotonin receptors, while binding only weakly to the cannabinoid receptors THC uses.
It doesn't appear to be intoxicating, though. In the 2024 placebo-controlled trial, a 20 mg dose produced no evidence of subjective drug effects or impairment on motor and cognitive tests. In the survey, the side effects people mentioned most were mild ones such as dry mouth, sleepiness, increased appetite and dry eyes, and 44% reported none. Most respondents, about 84%, also reported no withdrawal symptoms.
The bigger factor is THC. Some CBG gummies and vapes also contain THC, which is intoxicating, so the THC figure on the label tells you what to expect.
CBG versus CBD: research depth and receptor activity
Both start from CBGA, since CBD's acid form, CBDA, is one of its three branches. Beyond that, CBD has been studied far more widely in people than CBG, whose human evidence comes down to a survey and a few small trials. At the receptor level, CBG's strongest lab activity is at alpha-2 receptors and the TRPA1 channel, and it binds cannabinoid receptors only weakly. Neither one is intoxicating at the doses studied. Our side-by-side guide to CBG vs. CBD lays out the differences point by point.
CBGA explained
CBGA, or cannabigerolic acid, is the raw form the living plant makes and stores in its trichomes. It's the shared starting point for THCA, CBDA and CBCA. When CBGA is heated, or more slowly as plant material dries, it loses part of its structure and becomes CBG.
That's why lab reports often list both. A flower can show more CBGA than CBG because the conversion hasn't happened yet. Smoking, vaping or baking converts much of the CBGA into CBG, just as it turns THCA into THC.
Finding CBG: ratio gummies, vapes and flower lab results
CBG usually turns up in three places:
- Ratio gummies and tinctures: labels list milligrams of each cannabinoid per serving, such as 5 mg of CBG with 5 mg of THC. A 1:1 ratio means equal amounts.
- Vapes: some cartridges blend in CBG, and the label or lab report lists how much.
- Flower: a lab report shows CBG and CBGA separately. CBG-dominant flower is uncommon, so expect small numbers on most reports.
A ratio describes proportions, not strength. A 1:1 gummy with 5 mg of each cannabinoid and a 1:1 gummy with 10 mg of each share the same ratio, but the second has twice the THC. Check the milligrams of THC per serving first.
Questions about a label or a product? Bring them to a budtender at any of our Michigan stores.
CBG and drug tests
Standard urine drug screens are built to detect a THC breakdown product, not CBG. In a 2020 lab study, researchers added CBG to urine samples at 1,000 ng/mL and ran them through two common THC screening tests. CBG didn't trigger either test, though CBN, another minor cannabinoid, did.
The real risk is THC. Any product that contains THC, including ratio products that pair CBG with THC, can lead to a positive result, and hemp-derived products can carry trace amounts too. If you're subject to drug testing, check the lab report for THC and THCA, and when in doubt, skip it.
